Diclofenac/tolperisone controlled release

Drug Profile

Diclofenac/tolperisone controlled release

Alternative Names: Diclofenac SR/tolperisone SR; Diclofenac/tolperisone sustained release; Tolperisone SR/diclofenac SR; Tolperisone/diclofenac controlled release; Tolperisone/diclofenac sustained release

Latest Information Update: 21 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inventia Healthcare
  • Class Analgesics; Antirheumatics; Antiseptics; Antispasmodics; Muscle relaxants; Nonsteroidal anti-inflammatories; Phenylacetates; Propiophenones; Pyridines; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute pain

Most Recent Events

  • 21 Apr 2015 No recent reports of development identified - Phase-III for Acute pain in India (PO)
  • 27 Jan 2012 Inventia Healthcare completes a phase III trial in Acute pain (low back pain) in India (CTRI2011-10-002074)
  • 20 Oct 2011 Phase-III clinical trials in Acute pain in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top